Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature

Cantini, Luca; Pistelli, Mirco; Savini, Agnese; Bastianelli, Lucia; Mora, A. Della; Merloni, Filippo; Burattini, Maurizio; Berardi, Rossana

doi:10.3892/mco.2017.1495

Cited by 8 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Visceral disease in combination with ER/PgR expression and possibly HER2 FISH ratio shows some association with the duration of treatment response. This is in line with previous reports of factors associated with long-term survivorship in patients with HER2-positive metastatic breast cancer [10, 11].…”

Section: Discussionsupporting

confidence: 93%

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

et al. 2019

View full text Add to dashboard Cite

Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset of patients deriving long-term benefit from trastuzumab monotherapy alone and to identify potential predictive factors of long-term response. Methods This is an unplanned post-hoc analysis of patients randomized to Arm A (trastuzumab monotherapy). Patients were divided in two groups: patients with durable clinical benefit from trastuzumab monotherapy and short-term responders without durable clinical benefit from trastuzumab monotherapy Univariate and multivariate analyses of clinical characteristics correlating with response duration was performed. Results Eighty six patients were randomized in arm A, 24 patients (28%) were long-term responders and 62 (72%) were short-term responders with a 5y-overall survival (OS) of 54% (95% CI 31–72) and of 18% (95%CI 10–30), respectively. Absence of ER expression, absence of PgR expression and presence of visceral disease emerged as possible negative predictive factors for durable clinical benefit. Conclusion Durable clinical benefit can be achieved with trastuzumab monotherapy in a subgroup of HER2-positive patients with advanced disease and it is predictive for longer OS. Further investigations of predictive biomarkers are necessary to better characterize this subgroup of patients and develop further de-escalating strategies. Trial registration NCT00004935; first posted 27.01.2003, retrospectively registered.

show abstract

Section: Discussionsupporting

confidence: 93%

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

et al. 2019

View full text Add to dashboard Cite

show abstract

“…HER-2 gene is amplified or overexpressed in 10–34% of breast cancers and historically, HER-2-amplified metastatic breast cancer is an aggressive cancer. 47 In oral cancers, some studies reported the expression of c-erbB-2 as membranous 48 and the others as mixed, cytoplasmic and membranous 22 or even as cytoplasmic (only). The studies that examined HER-2 in OSCCs have reported divergent results with reference to pattern of expression.…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Dissanayeke

2019

Translational Research in Oral Oncology

View full text Add to dashboard Cite

Objective: To examine the immunohistochemical expression of four members of the type 1 growth factor receptor family in oral squamous cell carcinomas (OSCCs) and to correlate with clinical outcomes. Materials and methods: Sixty OSCCs from a patient cohort in Sri Lanka were included in the study. Five sections from each carcinoma were immunostained with antibodies to epidermal growth factor receptor (EGFR)/c-erbB-1, c-erbB-2/HER-2/neu, c-erbB-3/HER-3 and c-erbB-4/HER-4. Two clones were used to stain for c-erbB-2/HER-2/neu. Semiquantitative analysis of immunoreactivity was carried out by scoring the intensity of expression and proportions of positively stained cells. A logistic regression analysis was performed to examine positive expression against overall survival. Results: There was heterogenous expression of the four receptors, positivity ranging from 26% to 60%. Co-expression of all four markers was observed only in 1-3% of the tumours. Both membranous and cytoplasmic expressions were observed, EGFR showing predominantly membranous expression and c-erbB-2 showing only cytoplasmic staining. In logistic regression analysis, none of the growth factor receptors were significantly predictive of overall survival. Conclusion: Type 1 growth factor receptors are highly expressed in oral carcinomas, EGFR being the predominant marker.

show abstract

“…Next, as mentioned in the first part of this review paper, there are different types of investigational drugs (e.g., antibodies, inhibitors, ADC) and plausible drug combinations under consideration for improving treatment options for HER2 + patients. However, due to ethical and financial reasons, it is difficult to conduct clinical trials to evaluate all possible combinations [13,71,172]. Mathematical models can contribute to derive useful information in this regard.…”

Section: Mathematical Models Used For Breast Cancer Managementmentioning

confidence: 99%

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Padmanabhan

Kheraldine

Meskin

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast cancer is one of the major causes of mortality in women worldwide. The most aggressive breast cancer subtypes are human epidermal growth factor receptor-positive (HER2+) and triple-negative breast cancers. Therapies targeting HER2 receptors have significantly improved HER2+ breast cancer patient outcomes. However, several recent studies have pointed out the deficiency of existing treatment protocols in combatting disease relapse and improving response rates to treatment. Overriding the inherent actions of the immune system to detect and annihilate cancer via the immune checkpoint pathways is one of the important hallmarks of cancer. Thus, restoration of these pathways by various means of immunomodulation has shown beneficial effects in the management of various types of cancers, including breast. We herein review the recent progress in the management of HER2+ breast cancer via HER2-targeted therapies, and its association with the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) axis. In order to link research in the areas of medicine and mathematics and point out specific opportunities for providing efficient theoretical analysis related to HER2+ breast cancer management, we also review mathematical models pertaining to the dynamics of HER2+ breast cancer and immune checkpoint inhibitors.

show abstract

Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature

Cited by 8 publications

References 26 publications

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Expression and clinical significance of the receptors of the EGF family in oral squamous cell carcinomas

Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models

Contact Info

Product

Resources

About